Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Company Deals

Cellular Intelligence Acquires Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy Program, Plans AI-Driven Acceleration

Fineline Cube May 13, 2026
Company Deals

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Fineline Cube May 13, 2026
Policy / Regulatory

Hong Kong to Launch FDA-Style Medical Products Regulation Center by Year-End, Creating Gateway for Chinese Innovative Drugs

Fineline Cube May 13, 2026
Company Drug

Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials

Fineline Cube May 13, 2026
Company Drug

Servier’s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma

Fineline Cube May 13, 2026
Company Drug

Sandoz Launches Pyzchiva Biosimilar of J&J’s Stelara in US

Fineline Cube Feb 25, 2025

Switzerland-based Sandoz (SWX: SDZ) announced the launch of Pyzchiva, a biosimilar version of Johnson &...

Company

CDE Includes Chiral Tech’s Cerdelga Generic in Rare Disease Care Plan

Fineline Cube Feb 25, 2025

China’s Center for Drug Evaluation (CDE) announced the inclusion of Beijing Chiral Tech’s generic version...

Company Medical Device

Medtronic’s BrainSense Adaptive DBS Wins FDA Approval for Parkinson’s Treatment

Fineline Cube Feb 25, 2025

US-Irish medical device giant Medtronic (NYSE: MDT) announced that the US Food and Drug Administration...

Legal / IP

SMPA Suspends Indobufen Procurement After Patent Infringement Verdict

Fineline Cube Feb 25, 2025

Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) announced the suspension of procurement for indobufen, manufactured by...

Company Drug

Xellsmart’s iPSC Therapy XS-228 Receives FDA Approval for ALS Study

Fineline Cube Feb 25, 2025

Suzhou-based stem-cell startup Xellsmart announced that the U.S. FDA has approved its regulatory study of...

Company Drug

Huadong Medicine’s HDM1005 Receives NMPA Approval for OSA Treatment

Fineline Cube Feb 25, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its HDM1005, a long-acting GLP-1/GIP receptor...

Company Drug

Pfizer’s Hympavzi (Marstacimab) Launched in China’s Boao Lecheng Pilot Zone for Hemophilia

Fineline Cube Feb 25, 2025

Pfizer Inc. (NYSE: PFE) announced the implementation of its hemophilia therapy Hympavzi (marstacimab) in China’s...

Company Deals

Summit Therapeutics and Pfizer Collaborate on Ivonescimab-ADC Combo for Solid Tumors

Fineline Cube Feb 25, 2025

Summit Therapeutics Inc. (NASDAQ: SMMT), the U.S. partner of China-based Akeso Inc. (HKG: 9926) for...

Company

Dizal Pharma’s 2024 Revenues Surge 295% to RMB360M, Loss Narrows by RMB251M

Fineline Cube Feb 25, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial preview, showing annual revenues...

Company Drug

Bristol-Myers Squibb’s Opdivo-Yervoy Combo Nears FDA Approval for MSI-H Colorectal Cancer

Fineline Cube Feb 25, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the U.S. FDA has accepted its filing for...

Company Drug

CanSino Biologics Receives NMPA Approval for DTcP Hib MCV4 Combined Vaccine

Fineline Cube Feb 25, 2025

China-based vaccine specialist CanSino Biologics Inc. (HKG: 6185) announced that its absorbed diphtheria, tetanus, acellular...

Company Deals

MGI Tech Partners with Oncoclínicas&Co to Advance Precision Medicine in Brazil

Fineline Cube Feb 25, 2025

China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) has partnered with OC Medicina...

Company Drug

Boehringer Ingelheim’s Nerandomilast Receives NMPA Review for IPF Treatment

Fineline Cube Feb 25, 2025

Boehringer Ingelheim announced that its investigational drug nerandomilast has been accepted for review by the...

Company Drug

QYuns Therapeutics’ QX002N Meets Primary Endpoint in AS Phase III Study

Fineline Cube Feb 25, 2025

China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) announced that its Phase III study of...

Company Drug

Takeda’s Takhzyro Receives EMA Approval for New Administration Form in HAE Patients

Fineline Cube Feb 25, 2025

Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) announced that the European Medicines Agency (EMA) has approved...

Policy / Regulatory

National Allied Procurement Office Allows VBP Winners to Adjust MAH and Manufacturing Details

Fineline Cube Feb 24, 2025

The National Allied Procurement Office has issued a notification clarifying rules for China’s Volume-Based Procurement...

Company

Ipsen Posts 8.7% Revenue Growth in 2024, Driven by Rare Diseases and Oncology

Fineline Cube Feb 24, 2025

French biopharma firm Ipsen (EPA: IPN, OTCMKTS: IPSEY) reported an 8.7% year-on-year (YOY) increase in...

Company Drug

Meyer FSMP Hong Kong Secures NMPA Approval for First FSMP in Greater China

Fineline Cube Feb 24, 2025

Hong Kong-based Meyer FSMP Hong Kong Limited, an oncology-focused foods for special medical purpose (FSMP)...

Company Deals Drug

Pfizer Halts Global Development of Hemophilia B Gene Therapy Beqvez Amid Limited Demand

Fineline Cube Feb 24, 2025

Pfizer Inc. (NYSE: PFE) has terminated the development and commercialization of Beqvez (fidanacogene elaparvovec), its...

Company Deals

Jointown Pharmaceutical Partners with Shandong DYNE to Boost Pediatric Drug Distribution

Fineline Cube Feb 24, 2025

Jointown Pharmaceutical Group Co., Ltd (SHA: 600998), China’s largest private pharmaceutical distributor, has partnered with...

Posts pagination

1 … 206 207 208 … 665

Recent updates

  • Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform
  • Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials
  • Legend Biotech Reports 56% Q1 Revenue Growth to $305M, Driven by Carvykti Sales Surge and J&J Milestone Payment
  • Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms
  • Sichuan Kelun-Biotech Receives NMPA Approval for ITGB6-Targeted ADC SKB105 in Advanced Solid Tumors Following Crescent Biopharma Licensing Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Company Drug

Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials

Company

Legend Biotech Reports 56% Q1 Revenue Growth to $305M, Driven by Carvykti Sales Surge and J&J Milestone Payment

Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.